Investors / HighLight Capital
HighLight Capital
Venture capital
HighLight Capital is a private investment firm that invests in companies aiming to boost manufacturing efficiency and improve human wellness. It manages over US$3.8 billion and has offices in Tokyo, Shanghai, Hong Kong and Boston.
Invests inHealthcare & Biotech
In its own wordshealthcarebiotechlife sciencesmanufacturingwellness
Your fit with HighLight Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsHighLight Capital lists 17 checked portfolio companies on its own site and is named in 6 funding rounds. Its most frequent entry is Series A, 50% of the companies with a known first round. Its largest themes are Healthcare & Biotech (88%), Fintech (6%) and E-commerce & Marketplaces (6%). 53% of its companies are based in United States. It invests most often alongside Angelini Ventures, Bayern Kapital and Kurma Partners.
Counts come from funding rounds that name HighLight Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not HighLight Capital's whole history. Rounds on record name 6 companies; its own site lists 17. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundHighLight Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 50% |
| Series B | 50% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 4 | 0 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 44th | 17 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 95th | 88% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Angelini Ventures | 2 |
| Bayern Kapital | 2 |
| Kurma Partners | 2 |
| 3E Bioventures Capital | 1 |
| 5Y Capital | 1 |
| ARCH Venture Partners | 1 |
| Aisling Capital | 1 |
| BioRock Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1588%
- No longer answers00%
- Points to another company212%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 88% | 15% |
| Fintech | 6% | 12% |
| E-commerce & Marketplaces | 6% | 6% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Angelini Ventures
Compare HighLight Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with HighLight Capital| Date | Company | Stage |
|---|---|---|
| 10 Aug 2026 | Series B | |
| 17 Dec 2025 | Series A | |
| 8 Oct 2025 | Series A | |
| 10 Jul 2025 | Series B | |
| 6 May 2025 | Series B |
Round details for HighLight Capital
Amounts, full round histories and every co-investor in HighLight Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
17 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. | Healthcare & Biotech | Oct 2025Series A | Funding round | |
| Aureka Biotechnologies develops life-saving medicines using artificial intelligence and data-driven design | Healthcare & Biotech | Aug 2026Series B | Funding round | |
| Cullgen builds protein degraders and Degrader-Antibody Conjugates for the treatment of cancer, pain and inflammatory diseases | Healthcare & Biotech | Portfolio page | ||
| Hongene Biotech Corporation offers services and products related to oligonucleotide and mRNA synthesis and manufacturing | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Immusoft engineers B cells as biofactories for therapeutic protein delivery | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Medilink Therapeutics focuses on developing internationally competitive drug conjugates, as well as the latest generation of technologies and products with independent intellectual property rights and better therapeutic windows, to serve the unmet clinical needs. | Healthcare & Biotech | Portfolio page | ||
| Nuclidium develops next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer | Healthcare & Biotech | Jul 2025Series B | Funding round | |
| Nuevocor develops and tests medicines for treating cardiomyopathies | Healthcare & Biotech | May 2025Series B | Funding round | |
| Pharmaron provides contract research services for life science companies. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Singular Genomics develops a high throughput spatial multiomics technology for breakthroughs in precision diagnostics and personalized medicine. | Healthcare & Biotech | Portfolio page | ||
| T-CURX is a biotechnology company that develops autologous CAR-T cell therapies for cancer treatment | Healthcare & Biotech | Dec 2025Series A | Funding round | |
| TUNE provides a partner marketing platform for managing and measuring affiliate marketing programs. | FintechE-commerce & Marketplaces | Portfolio page | ||
| Yuwell introduces professional medical-grade products into households, enabling users to receive timely and effective treatment and care at home | Healthcare & Biotech | Portfolio page | ||
| Zentalis is developing a differentiated oral therapy that targets WEE1 kinase, a key regulator of cell-cycle progression. | Healthcare & Biotech | Portfolio page |
About this data
site last read 7 Nov 2026- Site
- hlcfund.com
- Last read
- 7 Nov 2026
- Watching since
- 7 Nov 2026
- Rounds since
- 6 May 2025
- Companies checked
- 17
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get HighLight Capital's profile as data
Pull HighLight Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/hlcfund.com
# also
GET /v1/firms/hlcfund.com/portfolio
GET /v1/firms/hlcfund.com/coinvestors
GET /v1/firms/hlcfund.com/news